A-674563

A-674563 is an orally active Akt1 inhibitor with a Ki of 11 nM.

Product Specifications

CAS Number

[552325-73-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/a-674563.html

Purity

99.87

Solubility

DMSO : 83.33 mg/mL (ultrasonic)

Smiles

N[C@@H](CC1=CC=CC=C1)COC2=CC(C3=CC4=C(C=C3)NN=C4C)=CN=C2

Molecular Formula

C22H22N4O

Molecular Weight

358.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Luo Y, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther, 2005, 4 (6), 977-986.|[2]Zhu QS, et al. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res, 2008, 68 (8), 2895-2903.|[3]Zou Y, et al. Pre-clinical assessment of A-674563 as an anti-melanoma agent. Biochem Biophys Res Commun. 2016 Aug 12;477 (1) :1-8.|[4]Xu L, et al. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells. Biochem Biophys Res Commun. 2016 Apr 15;472 (4) :662-8.|[5]Wang A, et al. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget. 2016 May 17;7 (20) :29131-42.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

Akt1

Citation 01

Cell Commun Signal. 2025 Apr 23;23 (1) :194.|Cell Signal. 2023 Sep:109:110753.|J Proteome Res. 2018 Oct 5;17 (10) :3360-3369.|Oncotarget. 2016 May 17;7 (20) :29131-42. |Aging. 2020 Nov 17;12 (22) :23114-23128.